StreetInsider.com News Articles

Form 4 biote Corp. For: Aug 10 Filed by: Beer Marc D

Wed, 12 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260812/26913342.html

Form 4 biote Corp. For: Aug 10 Filed by: Beer Marc D

Wed, 12 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260812/26913342.html

biote Corp. (BTMD) PT Lowered to $1.50 at B.Riley

Mon, 10 Aug 2026 08:18:07 -0400

B.Riley analyst Jeff Van Sinderen lowered the price target on biote Corp. (NASDAQ: BTMD) to $1.50 (from $2.00) while maintaining a Neutral rating.

biote Corp. (BTMD) PT Lowered to $2 at TD Cowen

Fri, 07 Aug 2026 08:56:42 -0400

TD Cowen analyst Jonna Kim lowered the price target on biote Corp. (NASDAQ: BTMD) to $2.00 (from $2.50) while maintaining a Buy rating.

biote Corp. (BTMD) Misses Q2 EPS by 25c

Wed, 05 Aug 2026 17:20:30 -0400

biote Corp. (NASDAQ: BTMD) reported Q2 EPS of ($0.23), $0.25 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $44.2 million versus the consensus estimate of $46.18 million.

For earnings history and earnings-related data on biote Corp. (BTMD) click here.

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025
Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

Wed, 22 Jul 2026 16:05:00 -0400

IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide second quarter financial results on Wednesday, August 5, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET the same day.

Conference Call Details

The conference call may be accessed by dialing (646) 307-1963 (U.S. toll-free) or (800) 715-9871 (International) and referencing conference ID: 1792102. The live webcast of the call can

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

Wed, 22 Jul 2026 16:05:00 -0400

Conference Call Details

The conference call may be accessed by dialing (646) 307-1963 (U.S. toll-free) or (800) 715-9871 (International) and referencing conference ID: 1792102. The live webcast of the call can

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

Wed, 22 Jul 2026 16:05:00 -0400

Conference Call Details

The conference call may be accessed by dialing (646) 307-1963 (U.S. toll-free) or (800) 715-9871 (International) and referencing conference ID: 1792102. The live webcast of the call can

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

Wed, 22 Jul 2026 16:05:00 -0400

Conference Call Details

The conference call may be accessed by dialing (646) 307-1963 (U.S. toll-free) or (800) 715-9871 (International) and referencing conference ID: 1792102. The live webcast of the call can

Form 4 biote Corp. For: Jun 12 Filed by: Peterson Robert Charles

Tue, 16 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260616/26655244.html

Form 4 biote Corp. For: Jun 12 Filed by: Peterson Robert Charles

Tue, 16 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260616/26655244.html

Form 4 biote Corp. For: Jun 08 Filed by: Christensen Bret

Wed, 10 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260610/26630844.html

Form 4 biote Corp. For: Jun 08 Filed by: Christensen Bret

Wed, 10 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260610/26630844.html

Form 4 biote Corp. For: Jun 08 Filed by: Beer Marc D

Wed, 10 Jun 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260610/26630832.html

Form 4 biote Corp. For: Jun 08 Filed by: Beer Marc D

Wed, 10 Jun 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260610/26630832.html